Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 4/2013

01-12-2013 | Interstitial Lung Disease (G Tino, Section editor)

Acute exacerbation of idiopathic pulmonary fibrosis: a proposal

Authors: Kerri A. Johannson, Harold R. Collard

Published in: Current Pulmonology Reports | Issue 4/2013

Login to get access

Abstract

Acute exacerbation of idiopathic pulmonary fibrosis (IPF) occurs in approximately 10 % of IPF patients annually, and is a leading cause of morbidity and mortality in this disease. Although currently defined as idiopathic acute worsening, acute exacerbation of IPF may in fact have a variety of causes, in particular infection and aspiration. Central to the pathobiology of clinically meaningful events is a diffuse injury to the IPF lung, manifest histopathologically as diffuse alveolar damage, and biologically as accelerated alveolar epithelial cell injury or repair. On the basis of these recent observations, we propose a new conceptual framework for acute exacerbation of IPF that removes the idiopathic requirement and focuses on the pathophysiological mechanism involved.
Literature
1.
•• Raghu G et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. These are the most recent internationally accepted consensus guidelines on the diagnosis and management of IPF.PubMedCrossRef
2.
Collard HR et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636–43.PubMedCrossRef
3.
•• Song JW et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356–63. This manuscript describes clinical features and outcomes in acute exacerbations of IPF for the largest descriptive cohort to date. It also reveals that acute exacerbation may occur after surgery.PubMedCrossRef
4.
Kondoh Y et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103(6):1808–12.PubMedCrossRef
5.
Kondo A, S.S. Acute exacerbation in idiopathic interstitial pneumonia (IIP). Intractable Diseases Research Foundation Publication No. 27. ed. Interstitial pneumonia of unknown etiology. 1989, Tokyo, Japan.: University of Tokyo Press.
6.
King Jr TE et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92–9.PubMedCrossRef
7.
Noble PW et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.PubMedCrossRef
8.
Richeldi L et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87.PubMedCrossRef
9.
Zisman DA et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620–8.PubMedCrossRef
10.
Mura M et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012;40(1):101–9.PubMedCrossRef
11.
Judge EP et al. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012;40(1):93–100.PubMedCrossRef
12.
Simon-Blancal V et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration. 2012;83(1):28–35.PubMedCrossRef
13.
Collard HR et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73.PubMedCrossRef
14.
Olson AL et al. Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest. 2009;136(1):16–22.PubMedCrossRef
15.
Johannson KA et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. (in press).
16.
Akira M et al. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(4):372–8.PubMedCrossRef
17.
Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005;128(5):3310–5.PubMedCrossRef
18.
Churg A et al. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol. 2007;31(2):277–84.PubMedCrossRef
19.
Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. Histopathology. 2011;58(4):525–30.PubMedCrossRef
20.
Konishi K et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;180(2):167–75.PubMedCrossRef
21.
• Collard HR et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(1):L3–7. This manuscript reports an investigation of the plasma biomarker profile for acute exacerbation of IPF, demonstrating it is predominantly suggestive of increased alveolar epithelial cell injury and/or activity.PubMedCrossRef
22.
Kakugawa T et al. Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis. Cell Stress Chaperones. 2013.
23.
Kahloon RA et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med. 2012;187(7):768–75.CrossRef
24.
Huie TJ et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology. 2010;15(6):909–17.PubMedCrossRef
25.
• Wootton SC et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(12):1698–702. This study demonstrated that viral infection is present in a minority of cases of acute exacerbation of IPF.PubMedCrossRef
26.
• Lee JS et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012;39(2):352–8. This study revealed that elevated pepsin levels are present in the bronchoalveolar lavage of patients with acute exacerbation of IPF, suggesting that aspiration is responsible for a subgroup of cases.PubMedCrossRef
27.
Tobin RW et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158(6):1804–8.PubMedCrossRef
28.
Raghu G et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136–42.PubMedCrossRef
29.
Raghu G et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129(3):794–800.PubMedCrossRef
30.
Linden PA et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg. 2006;131(2):438–46.PubMedCrossRef
31.
• Lee JS et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369–76. This study revealed that anti-acid therapy may reduce the incidence of acute exacerbation of IPF in a clinical trial cohort.CrossRef
32.
Kondoh Y et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med. 2006;100(10):1753–9.PubMedCrossRef
33.
Sakamoto S et al. Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study. Intern Med. 2011;50(2):77–85.PubMedCrossRef
34.
Sugiura H et al. Acute exacerbation of usual interstitial pneumonia after resection of lung cancer. Ann Thorac Surg. 2012;93(3):937–43.PubMedCrossRef
35.
Suzuki H et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today. 2011;41(7):914–21.PubMedCrossRef
36.
Yano M et al. Post-operative acute exacerbation of pulmonary fibrosis in lung cancer patients undergoing lung resection. Interact Cardiovasc Thorac Surg. 2012;14(2):146–50.PubMedCrossRef
37.
Mizuno Y et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012;41(6):e161–5.PubMedCrossRef
38.
Sakamoto K et al. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med. 2012;106(3):436–42.PubMedCrossRef
39.
Ghatol A, Ruhl AP, Danoff SK. Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the literature. Lung. 2012;190(4):373–80.PubMedCrossRef
40.
Rangappa P, Moran JL. Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis. Crit Care Resusc. 2009;11(2):102–9.PubMed
41.
Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J. 2004;11(2):117–22.PubMed
42.
Collard HR et al. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med. 2007;101(9):2011–6.PubMedCrossRef
43.
Horita N et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2011;50(3):189–95.PubMedCrossRef
44.
Abe S et al. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis. Intern Med. 2012;51(12):1487–91.PubMedCrossRef
45.
Tachibana K et al. Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serum IL-7 as a prognostic marker. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):113–22.PubMed
46.
Noma S et al. Two cases of acute exacerbation of interstitial pneumonia treated with polymyxin B-immobilized fiber column hemoperfusion treatment. Intern Med. 2007;46(17):1447–54.PubMedCrossRef
47.
Seo Y et al. Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2006;45(18):1033–8.PubMedCrossRef
48.
Oishi K et al. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013;61(1):84–9.PubMedCrossRef
49.
Inase N et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med. 2003;42(7):565–70.PubMedCrossRef
50.
Sakamoto S et al. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49(2):109–15.PubMedCrossRef
51.
Kondoh Y et al. Recombinant thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis, in B102. Interstitial lung disease: novel management and outcome strategies. American Thoracic Society. p. A3811.
52.
Kondoh Y et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):103–10.PubMed
53.
Moeller A et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(7):588–94.PubMedCrossRef
54.
Fujimoto K et al. Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur Radiol. 2012;22(1):83–92.PubMedCrossRef
Metadata
Title
Acute exacerbation of idiopathic pulmonary fibrosis: a proposal
Authors
Kerri A. Johannson
Harold R. Collard
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 4/2013
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-013-0065-x

Other articles of this Issue 4/2013

Current Pulmonology Reports 4/2013 Go to the issue

Interstitial Lung Disease (G Tino, Section editor)

Combined pulmonary fibrosis and emphysema

Allergy and Immunology (SP Peters and JJ Oppenheimer, Section editors)

The small airways in asthma

Respiratory Infections (CL Daley, Section Editor)

Diagnosis and treatment of latent tuberculosis infection: an update

Respiratory Infections (CL Daley, Section Editor)

Management of drug-resistant tuberculosis

Interstitial Lung Disease (G Tino, Section editor)

Idiopathic pulmonary fibrosis co-morbidity: thromboembolic disease and coronary artery disease

Interstitial Lung Disease (G Tino, Section editor)

Lung cancer in idiopathic pulmonary fibrosis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits